Larimar Therapeutics (LRMR)
(Delayed Data from NSDQ)
$7.44 USD
+0.29 (4.06%)
Updated Aug 8, 2024 03:59 PM ET
After-Market: $7.44 0.00 (0.00%) 6:36 PM ET
3-Hold of 5 3
D Value F Growth D Momentum F VGM
Price, Consensus and EPS Surprise
LRMR 7.44 +0.29(4.06%)
Will LRMR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for LRMR based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for LRMR
The Zacks Analyst Blog Highlights Biogen, Ionis Pharmaceuticals, GSK, PTC Therapeutics and Larimar Therapeutics
Biotech Stock Roundup: BIIB's Acquisition, PTCT, LRMR Gain on Updates & More News
LRMR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Larimar (LRMR) Up on Lifting of Partial Clinical Hold on FA Study
Nektar Therapeutics (NKTR) Q1 Earnings & Revenues Beat
Larimar (LRMR) Upgraded to Strong Buy: What Does It Mean for the Stock?
Other News for LRMR
Commit To Purchase Larimar Therapeutics At $5, Earn 20.3% Annualized Using Options
Buy Rating Affirmed: Larimar Therapeutics’ Strategic Expansion and Promising Clinical Progress
Larimar Therapeutics GAAP EPS of -$0.34
Larimar: Q2 Earnings Snapshot
Larimar Therapeutics Reports Second Quarter 2024 Operating and Financial Results